0086-571-89925085
NMR
CNMR
HPLC
LC-MS
Iptacopan, also known as LNP023, is a complement Factor B Inhibitor (IC50=10 nM). LNP023 improves LN in MRL/lpr mice.
The mechanism is as follows: LNP023 binds to CFB to inhibit the activation of the alternative complement pathway.
LNP023 treatment for LN may also play a role in regulating the protein expression of AKT, TNF-α, and STST3.
LNP023 showed low clearance and high bioavailability (62.2%).
Furthermore, four minor metabolites from rat plasma were detected and identified by LC combined with high-resolution mass spectrometry.
The metabolic pathways were O-deethylation (M1), hydroxylation (M4), oxidation (M3), and acyl-glucuronidation (M2).
1646321-63-2 (HCl) 1644670-37-0 (free base)
